APLTApplied Therapeutics
About Applied Therapeutics
Applied Therapeutics (NASDAQ:APLT) focuses on developing novel treatments in areas where there is a significant unmet medical need. With a dedicated team of experienced professionals, the company is currently advancing a pipeline of therapeutic candidates aimed at addressing conditions in metabolic diseases, diabetic complications, and neurodegenerative diseases. Their approach combines innovative science with a deep understanding of the diseases they aim to treat, striving to bring transformative therapies to patients who currently have limited or no treatment options. Central to their mission is a commitment to rigorous scientific methodologies and patient safety, underscoring their goal to improve lives through groundbreaking medical advancements.
What is APLT known for?
Snapshot
Public US
Ownership
2016
Year founded
34
Employees
New York, United States
Head office
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
New York City, US
Products and/or services of Applied Therapeutics
- AT-007, a central nervous system penetrant Aldose Reductase inhibitor for Galactosemia.
- AT-001, an aldose reductase inhibitor for diabetic cardiomyopathy.
- AT-003, an ARI designed for the treatment of diabetic retinopathy.
- Development of novel therapies targeting rare diseases with high unmet medical need.
- Exploration of AT-007's effectiveness in SORD Deficiency, a metabolic disorder.
Applied Therapeutics executive team
- Mr. Les D. FuntleyderInterm CEO, CFO, Principal Financial Officer & Director
- Mr. Corwin Dale HooksChief Commercial Officer
- Mr. Constantine ChinoporosCOO & Chief Business Officer
- Ms. Catherine ThorpeInterim Chief Accounting Officer
- Ms. Reena Thomas ColacotHead of Quality
- Dr. Todd F. Baumgartner M.D., M.P.H.Chief Regulatory Officer
- Dr. Evan Prescott Bailey M.D.Chief Medical Officer
- Ms. Dottie CaplanExecutive Vice President of Patient Advocacy & Government Affairs.